Emory University’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Emory University’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-172,524	Closed	-$1.84M	–	49
2018 Q4	$1.84M	Buy	+172,524	New	+$2.27M	1.45%	27
2018 Q3	–	Sell	-179,568	Closed	-$2.2M	–	51
2018 Q2	$2.2M	Sell	179,568 -66,843	-27%	-$840K	1.46%	32
2018 Q1	$2.36M	Buy	+246,411	New	+$2.66M	1.68%	27

Other funds holding DRNA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Emory University's DRNA Position: Q1 2019 in Review

Emory University sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2019, closing a stake of 172,524 shares — an estimated $1.84M sold.

Emory University first reported a position in DRNA in Q1 2018 and held it in 3 quarters. The position peaked at $2.36M in Q1 2018. 98 funds tracked by Wall St. Rank hold DRNA as of Q1 2019.

Emory University reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Emory University sold 172,524 Dicerna Pharmaceuticals, Inc. shares in Q1 2019, an estimated $1.84M.
Emory University first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 3 quarters.
Emory University's Dicerna Pharmaceuticals, Inc. position peaked at $2.36M in Q1 2018.
98 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2019.

Based on Emory University's 13F filing for Q1 2019, filed 9 May 2019.